Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clin Mol Hepatol 2023;29(3):779-793. Published online May 15, 2023
Background/Aims To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea.
Methods We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.
Results According to data from 2018–2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population.
Conclusions Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.
Citations
Citations to this article as recorded by
Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Infection and Public Health.2026; 19(2): 103076. CrossRef
2025 KASL clinical practice guidelines for management of hepatitis C Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung Clinical and Molecular Hepatology.2026; 32(1): 1. CrossRef
AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim Journal of Hepatology.2025; 82(3): 456. CrossRef
Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021 Si Yang, Yujiao Deng, Yi Zheng, Jing Zhang, Dongdong He, Zhijun Dai, Changcun Guo Hepatology International.2025; 19(2): 441. CrossRef
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults Donghee Kim, Won Kim, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(1): e5. CrossRef
Etiologic, epidemic, medical and economic aspects of hepatocellular carcinoma N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev Сибирский научный медицинский журнал.2025; 45(1): 6. CrossRef
HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn Clinical and Molecular Hepatology.2025; 31(2): e163. CrossRef
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiven Eun Sun Jang Clinical and Molecular Hepatology.2025; 31(2): 596. CrossRef
Temporal and geospatial patterns of hepatitis C virus prevalence: a longitudinal examination using national health insurance service data in the Republic of Korea (2005–2022) Hwa Young Choi, Moran Ki BMC Public Health.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults” Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong Clinical and Molecular Hepatology.2025; 31(2): e149. CrossRef
Incidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B Hye Won Lee, Sungshin Kwon, Yeo Rae Moon, Hyunjung Ahn, Juyeon Lee, Sang‐Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(6): 1586. CrossRef
A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Nishi Prabdial-Sing, Victoria Turnier, Jeffrey V Lazarus, Imam Waked, John W Ward, Angelica Miranda, Aya Sugiyama, Behzad Hajarizadeh, Carlos Varaldo, Ca The Lancet Gastroenterology & Hepatology.2025; 10(7): 671. CrossRef
Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysis Alexander J Stockdale, Bethany Holt, Ajeet Singh Bhadoria, Abhishek Sadasivan, Daniel Ikeda, Todd Pollack, Janus P Ong, Thuy Pham, David B Duong, Vy Nguyen, Gibril Ndow, Roger Chou, Philippa Easterbrook The Lancet Gastroenterology & Hepatology.2025; 10(11): 1013. CrossRef
Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study Gwang Hyeon Choi, Young-Hoon Chon, Do Hoon Kwon, Sung Nam Jo, Og-Jin Jang, Kyung-Ah Kim, Dahye Baik, Eun Sun Jang, Sook-Hyang Jeong Gut and Liver.2025; 19(5): 725. CrossRef
Etiological, Epidemiological, and Medical-Economic Aspects of Hepatocellular Carcinoma (A Review) N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev Cell and Tissue Biology.2025; 19(6): 525. CrossRef
Monitoring and evaluation of community interventions for viral hepatitis among migrants and refugees: a Delphi-based study Domenico Pascucci, Aina Nicolàs, Abdelrahman Taha, Jeffrey V Lazarus, Matteo Di Pumpo, Vittoria Tricomi, Francesco Di Berardino, Carlo La Vecchia, José A Perez-Molina, Giuseppe Colucci, Camila A Picchio, Angelo Maria Pezzullo, Stefania Boccia Journal of Global Health.2025;[Epub] CrossRef
Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study Oeuk Jeong, Changhee Chu, Jungyeon Kim, Jae Seung Lee, Jun Yong Park, Kyung Eun Lee, Jaehyun Seong, Min Jin Go BMC Infectious Diseases.2025;[Epub] CrossRef
Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study Won Sohn, Soo Young Park, Tae Hee Lee, Young Eun Chon, In Hee Kim, Byung-Seok Lee, Ki Tae Yoon, Jae Young Jang, Yu Rim Lee, Su Jong Yu, Won-Mook Choi, Sang Gyune Kim, Dae Won Jun, Joonho Jeong, Ji Hoon Kim, Eun Sun Jang, Hwi Young Kim, Sung Bum Cho, Byoun eClinicalMedicine.2024; 73: 102671. CrossRef
Linvencovir: Paving the way for functional cure in hepatitis B Jiwon Yang, Jonggi Choi Clinical and Molecular Hepatology.2024; 30(2): 164. CrossRef
Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi Global Health & Medicine.2024; 6(6): 404. CrossRef
Activation of Nrf2 and FXR via Natural Compounds in Liver Inflammatory Disease Marta Belka, Aleksandra Gostyńska-Stawna, Maciej Stawny, Violetta Krajka-Kuźniak International Journal of Molecular Sciences.2024; 25(20): 11213. CrossRef
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study” Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong Clinical and Molecular Hepatology.2024; 30(4): 997. CrossRef
Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study” Eun Ju Cho Clinical and Molecular Hepatology.2024; 30(4): 663. CrossRef
Background/Aims Galectin-3 plays a key pathogenic role in cardiac hypertrophy and heart failure. The present study aimed to investigate the effects of galectin-3 on cardiomyopathy – related factors and cardiac contractility in a rat model of cirrhotic cardiomyopathy.
Methods Rats were divided into two sets, one for a functional study, the other for cardiac contractile-related protein evaluation. There were four groups in each set: sham operated and sham plus N-acetyllactosamine (N-Lac, a galectin-3 inhibitor; 5 mg/kg); bile duct ligated (BDL) and BDL plus N-Lac. Four weeks after surgery, ventricular level of galectin-3, collagen I and III ratio, tumor necrosis factor alpha (TNFα), and brain natriuretic peptide (BNP) were measured either by Western blots or immunohistochemistry or enzyme-linked immunosorbent assay. Blood pressure was measured by polygraph recorder. Cardiomyocyte contractility was measured by inverted microscopy.
Results Galectin-3 and collagen I/III ratio were significantly increased in cirrhotic hearts. TNFα and BNP were significantly increased in BDL serum and heart compared with sham controls. Galectin-3 inhibitor significantly decreased galectin-3, TNFα, and BNP in cirrhotic hearts but not in sham controls. N-Lac also significantly improved the blood pressure, and systolic and diastolic cardiomyocyte contractility in cirrhotic rats but had no effect on sham controls.
Conclusion Increased galectin-3 in the cirrhotic heart significantly inhibited contractility via TNFα. Inhibition of galectin-3 decreased the cardiac content of TNFα and BNP and reversed the decreased blood pressure and depressed contractility in the cirrhotic heart. Galectin-3 appears to play a pathogenic role in cirrhotic cardiomyopathy.
Citations
Citations to this article as recorded by
Apoptosis in Cardiac Conditions Including Cirrhotic Cardiomyopathy Fengxue Yu, Dae Gon Ryu, Ki Tae Yoon, Hongqun Liu, Samuel S. Lee International Journal of Molecular Sciences.2025; 26(13): 6423. CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
Galectin-3: A Multitasking Protein Linking Cardiovascular Diseases, Immune Disorders and Beyond Mariarosaria Morello, Gisella Titolo, Saverio D’Elia, Silvia Caiazza, Ettore Luisi, Achille Solimene, Chiara Serpico, Andrea Morello, Francesco Natale, Paolo Golino, Plinio Cirillo, Giovanni Cimmino Targets.2025; 3(4): 34. CrossRef
Galectin-3 as a therapeutic target in pulmonary hypertension: Molecular mechanisms, drug development directions, and emerging clinical applications Antonín Sedlář, Pavla Bojarová, František Kolář, Vladimír Křen, Lucie Bačáková Biomedicine & Pharmacotherapy.2025; 193: 118756. CrossRef
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee JHEP Reports.2024; 6(1): 100911. CrossRef
Cirrhotic cardiomyopathy: Pathogenesis, clinical features, diagnosis, treatment and prognosis Francisca Almeida, Alexandra Sousa Revista Portuguesa de Cardiologia.2024; 43(4): 203. CrossRef
Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities Hongqun Liu, Daegon Ryu, Sangyoun Hwang, Samuel S. Lee International Journal of Molecular Sciences.2024; 25(11): 5849. CrossRef
Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee Pharmaceuticals.2023; 16(7): 978. CrossRef
Chenodeoxycholic Acid Improves Embryo Implantation and Metabolic Health through Modulating Gut Microbiota–Host Metabolites Interaction during Early Pregnancy Meixia Chen, Ying Zhao, Haifeng Ji, Lu Li, Hui Liu, Sixin Wang, Dongyan Zhang, Jingdong Yin, Jing Wang, Xin Zhang Antioxidants.2023; 13(1): 8. CrossRef
Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study Melisa Cetin, Ping Yip, Zhou-Hao Liu Future Healthcare Journal.2023; 10: S18. CrossRef
Temporal profile of cerebrospinal fluid galactin-3 and associated cytokine responses after severe traumatic brain injury in patients: a retrospective study Melisa Cetin, Ping Yip, Wing Sze Leung, Zhou-Hao Liu Clinical Medicine.2023; 23(6): 81. CrossRef
Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee Frontiers in Network Physiology.2022;[Epub] CrossRef
Collagen-binding fibroblast growth factor ameliorates liver fibrosis in murine bile duct ligation injury Qiangqiang Shi, Susu Wei, Zhi Chao Li, Jing Xu, Yaxin Li, Chuanlong Guo, Xianggen Wu, Chunying Shi, Guohu Di Journal of Biomaterials Applications.2022; 37(5): 918. CrossRef
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Myung Ji Goh, Wonseok Kang, Seung Up Kim European Journal of Gastroenterology & Hepatology.2023; 35(2): 191. CrossRef
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea Min Jin Lee, Sung Won Chang, Ji Hoon Kim, Young-Sun Lee, Sung Bum Cho, Yeon Seok Seo, Hyung Joon Yim, Sang Youn Hwang, Hyun Woong Lee, Young Chang, Jae Young Jang Investigational New Drugs.2021; 39(1): 260. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Effect of urea cream on sorafenib-associated hand–foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study Young-Sun Lee, Young K. Jung, Ji H. Kim, Sung B. Cho, Do Y. Kim, Moon Y. Kim, Hyung J. Kim, Yeon S. Seo, Ki T. Yoon, Young M. Hong, Jeong-Hoon Lee, Hyun W. Lee, Hyung J. Yim, Byoung K. Jang, Eun S. Jang, Jae Y. Jang, Sang Y. Hwang European Journal of Cancer.2020; 140: 19. CrossRef
First
Prev
